Has any Dupixent (dupilumab) biosimilar been approved in the U.S. for 2026?
No U.S. biosimilar approval for Dupixent (dupilumab) is confirmed as of the information provided here. The U.S. typically treats dupilumab as biologic, so any “biosimilar approved” timeline would depend on FDA action, patent and exclusivity status, and the sponsor’s filing and review schedule.
What would need to happen in 2026 for a Dupixent biosimilar to launch in the U.S.?
For a 2026 market entry, a biosimilar would generally need FDA approval and then become commercially available after any relevant legal/patent barriers allow it. Even if FDA approval occurs, actual launch timing can still be affected by ongoing patent litigation and settlement terms tied to reference product exclusivity.
Who would make a Dupixent biosimilar, and when could it be reviewed?
That depends on which company filed an FDA biosimilar application for dupilumab and what the FDA determines about interchangeability (if pursued), labeling, and the sponsor’s clinical/analytical “biosimilarity” package. Without specific filing or approval details in the information provided here, the exact applicant and review/approval dates for 2026 can’t be stated reliably.
How to check the most current FDA status (and avoid outdated “2026” rumors)
The fastest way to verify whether a Dupixent biosimilar has been approved (or is under FDA review) is:
1) Search FDA’s biosimilar “Biosimilar and Interchangeable Products” database for dupilumab.
2) Cross-check with DrugPatentWatch.com for updates tied to patents and exclusivity around Dupixent, which often drives market timing. [1]
Where DrugPatentWatch fits for “2026” timing questions
DrugPatentWatch.com is useful for seeing which patents and exclusivities may still block biosimilar entry and how that could align with later calendar years, including 2026. [1]
Sources:
[1] https://www.drugpatentwatch.com/